Asset Details
Do you wish to reserve the book?
Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival
Do you wish to request the book?
Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival
2015
Overview
Examining for new BC biomarkers has proven that kallikrein-related peptidase (KLK) family members represent promising serum and/or tissue molecular tools for early diagnosis, effective prognosis, and treatment monitoring of patients. The aim of this study was to investigate, the previously unexplored, prognostic significance of
KLK8
in BC.
KLK8
mRNA expression was quantitatively analyzed in 150 cancerous and 100 corresponding normal breast tissue specimens via a SYBR Green-based Real-Time PCR methodology. Expression data and patients’ clinicopathological parameters were used for extensive biostatistical analyses, including internal validation.
KLK8
mRNA expression was significantly downregulated in the cancerous tissue part relative to the non-cancerous counterpart (
P
< 0.001), in the majority of the paired breast tissue samples.
KLK8
expression was associated with advanced TNM stage (
P
= 0.019) and positive nodal status involvement (
P
= 0.044). Triple negative (TNBC) and HER2 overexpressing tumors exhibited higher
KLK8
expression levels (
P
< 0.001), compared to Luminal A and B molecular subtypes. Kaplan–Meier survival curve analysis revealed that BC patients with high
KLK8
expression had significantly shorter disease-free survival (DFS) intervals (
P
< 0.001) compared to those belonging in the
KLK8
-low expression group. Cox univariate analysis confirmed the association between
KLK8
expression, analyzed as a continuous variable, and poor patients’ outcome (Hazard ratio [HR] = 3.28,
P
< 0.001). Most importantly, multivariate analysis showed that
KLK8
expression is a strong and independent predictor of adverse DFS in BC ([HR] = 2.74;
P
= 0.002). Our results show that
KLK8
mRNA expression is associated with aggressive tumor characteristics and it can serve as a novel independent biomarker of unfavorable prognosis for BC patients.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
